ENCCS Work with Compular AB: final report
As ENCCS, we are parties in the FF4EuroHPC experiment grant awarded to Compular AB with the goal of optimizing the CHAMPION software
ENCCS Industry Days 2022
ENCCS is organizing the Swedish HPC Industry Day 2022, 10-11 October. This event will provide a comprehensive introduction to HPC targeted toward a broad audience, for example:
Trafikverket – Project update
Various methods for sequence-to-sequence modeling have been reported in the previous blog post. While the results were promising, such models do not apply to a more complex traffic network for […]
RISE Accesses VEGA
RISE NLU Group will train English BERT model using multiple GPUs on the EuroHPC JU system Vega.
Icarus Simulations AB Accesses EuroHPC JU system Vega
In the project, Icarus aims to focus on development for industrial and commercial applications in the aviation, marine and, automotive industry.
Successful application of Compular to the FF4EuroHPC program
Compular develops cutting-edge analysis tools for molecular dynamics simulations. The awarded project will fund a computational experiment in partnership with Stiftelsen Chalmers Industriteknik, Enerpoly, and ENCCS.
Trafikverket – Project update
Analysis of traffic flow at E4S (southbound) using deep learning (DL) methods is the subject of an ongoing collaboration between TV, KTH, and ENCCS. The project consists of two parts: […]
Traffic Flow and Deep Neural Networks
Modelling traffic flow on a specific part of the E4S using deep neural networks. The results give a hint at the most appropriate models for such modeling.
Thermo-Calc Software AB to access VEGA
The project leverages the power of HPC and first-principles-based calculations to accelerate the development of CALPHAD thermodynamic and kinetic databases that bring the feasibility of alloys-by-design to reality.
Drug Research and HPC. Moroxite AB & Forcelab AB Access VEGA System
Moroxite develops targeted drug delivery strategies for breakthrough therapies. Forcelab provides in silico insight into the drug development pipeline. The access to VEGA will help the companies advance their in silico drug discovery program and accelerate the testing of drug delivery methodologies.